Direct answer: The FDA published a discussion paper on the regulation of the generation of artificial intelligence on 18 August 2026, seeking comments on risk assessment, pre-market evaluation and post-market monitoring. The FDA made it clear that the document was intended for discussion only, was not a draft guide or final guide, and did not propose or implement new regulatory policies. The deadline for submissions, which is now closed on 19 October 2026, is the nature of the document, its current status and the business proposals set out below; Specific products should be judged in the official language.

What is this file, at what stage?

The regulatory document and its status referred to in this paper is based on the original FDA page listing. The discussion paper does not itself constitute a guide or a new policy; The period of opinion has ended and it cannot be argued that the new claim has entered into force on this basis.

A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.

Which enterprises and products need attention?

Manufacturers, software developers and post-market monitoring teams that develop or declare the production of AI medial device.

It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.

Where is the change from what was previously requested?

The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.

Direct answer:The FDA published a discussion paper on the regulation of the generation of artificial intelligence on 18 August 2026, seeking comments on risk assessment, pre-market evaluation and post-market monitoring. The FDA made it clear that the document was intended for discussion only, was not a draft guide or final guide, and did not propose or implement new regulatory policies. The deadline for submissions, 19 October 2026, is now closed.

The framework or question raised in the discussion paper should not be expressed as an existing FDA mandatory requirement. Whether the generator AI function constitutes medical device and the applicable path still needs to be judged against the specific design of the intended use, function, risk and product.
  • Generate AI medical approach to risk assessment.
  • Non-clinical baseline tests and clinical confirmations that may be of concern in pre-market evaluations.
  • Post-market monitoring commensurate with the risk.
  • Issues related to the basic model and proxy AI system.
  1. Determine how the intended use of the product, the target user, the use environment and the AI output influence clinical decision-making.
  2. Documenting models, training and validation data, version changes, performance boundaries and risk control methods.
  3. Assessment of software changes by product path, network security, labelling and post-market monitoring arrangements.
  4. The document was cited explicitly as a discussion paper and did not set out the envisaged framework as a statutory obligation.

Key dates and transitional arrangements

The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.

  • 18 August 2026: Date of issuance of the document (as expressed in the original language of the adjacent official).
  • 19 October 2026: Comments/due date of submission (as expressed in the original language of the neighbouring Government).

The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.

How can Chinese companies prepare?

  1. Integrate model uses, training/verification data, export risks, human causes, change control and post-market monitoring into product risk profiles; Waiting for FDA follow-up official documents.
  2. Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
  3. If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.

For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.

Exceptions, pending confirmations and common misreading

  • The discussion paper does not itself constitute a guide or a new policy; The period of opinion has ended and it cannot be argued that the new claim has entered into force on this basis.
  • When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
  • Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.

Official information and reconciliation records

(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.

Next

Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.